1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Hepatitis D - Epidemiology Forecast to 2030

Hepatitis D - Epidemiology Forecast to 2030

  • January 2021
  • 80 pages
  • ID: 6010465
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Hepatitis D Virus (HDV) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted HDV epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hepatitis D Virus (HDV) Understanding
Hepatitis D is caused by infection with the hepatitis D virus (HDV), also known as Delta Virus, and is considered to be the most severe form of viral hepatitis in humans due to more rapid progression toward liver-related death and hepatocellular carcinoma. HDV occurs only in individuals positive for the hepatitis B virus (HBV) surface antigen (HBsAg) as HDV is a defective RNA viroid that requires HBsAg for transmission. HDV shares common modes of transmission as HBV and can be acquired either as co-infection or super-infection to HBV. Simultaneous infection (i.e. co-infection) with HBV and HDV can lead to a mild-to-severe or even fulminant hepatitis, whereas the super-infection of HDV on chronic hepatitis B accelerates progression to a more severe disease in all ages and in 70?90% of people.
The mode of transmission is commonly through contact with blood or other body fluids, including sexual contact with an infected partner, injection-drug use that involves sharing needles, syringes, or drug-preparation equipment and needle sticks or exposures to sharp instruments. Vertical transmission from mother to child is rare. Infection with HDV can worsen symptoms of HBV infection or hepatitis B-associated liver disease. It can cause symptoms to occur in people who previously did not have symptoms of HBV infection. The symptoms of HDV infection are similar to those experienced with HBV infection and can include yellowing of the skin and eyes (jaundice), gastrointestinal (GI) issues such as nausea, vomiting, and abdominal pain, tiredness, loss of appetite, dark-colored urine, joint pain, etc.
The severity of hepatitis D is influenced by the HDV genotype. Although infection with multiple genotypes may occur in patients at high risk of repeated exposure such as injecting drug users, a single genotype usually predominates with >10% of the viral load being represented by the minor strain. There are at least 8 genotypes (genetic variants) of HDV based on 14–38% sequence variation. These genotypes are associated with different long-term outcomes. Genotype 1 chronic HDV super-infection usually leads to a rapid progression to cirrhosis. Genotypes 2 and 4 cause a milder disease over a longer time course whereas genotype 3 is associated with advanced necroinflammatory.

Hepatitis D Virus (HDV) Diagnosis
The diagnosis of HDV is based on the medical history, a physical exam, and blood tests of the patients. HDV infection is diagnosed by high levels of Immunoglobulin G (IgG) and Immunoglobulin M (IgM) anti-HDV. As cases of hepatitis D are not clinically distinguishable from other types of acute viral hepatitis, diagnosis can be confirmed only by testing for the presence of antibodies against HDV and/or HDV RNA. The doctor may recommend tests to find out whether the patient has liver damage or how much liver damage or to rule out other causes of liver disease. These tests may include elastography, a special ultrasound that measures the stiffness of the liver, liver enzyme function tests, and a liver biopsy, wherein a doctor uses a needle to take a small piece of tissue from the liver.

Epidemiology Perspective
The HDV epidemiology division provides insights about the historical and current HDV patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
In the year 2017, the Total Diagnosed Prevalent cases of HDV was 204,976 in the 7MM which are expected to grow during the study period, i.e., 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted HDV epidemiology [segmented as Total Diagnosed Prevalent Cases of HDV, Gender-specific Diagnosed Prevalent Cases of HDV, Age-specific Diagnosed Prevalent Cases of HDV, Diagnosed Prevalent Cases of HDV by Impact on Liver, and Treated cases of HDV] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- HDV Epidemiology
Estimates show that the highest cases of HDV in the 7MM were in the United States, followed by Japan, Germany, Italy, Spain, the United Kingdom, and France in 2017.
• In the United States, the total diagnosed prevalent cases of HDV was 112,673 cases in the year 2017 which are expected to grow during the study period, i.e., 2017–2030.
• In the year 2017, the total diagnosed prevalent cases of HDV were 64,845 cases in EU-5 which are expected to grow during the study period, i.e., 2017–2030.
• In Japan, the total diagnosed prevalent cases of HDV was 27,458 cases in the year 2017 which are expected to grow during the study period, i.e., 2017–2030.

Scope of the Report
• The HDV report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The HDV Report and Model provide an overview of the risk factors and global trends of HDV in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of HDV in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of HDV.
• The report provides the segmentation of the HDV epidemiology by total diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the HDV epidemiology by gender-specific diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the HDV epidemiology by age-specific diagnosed prevalent cases in the 7MM.
• The report provides the segmentation by diagnosed prevalent cases of HDV by the impact on the liver in the 7MM.
• The report provides the segmentation of the HDV epidemiology by treated cases in the 7MM.

Report Highlights

• 11-Year Forecast of HDV epidemiology
• 7MM Coverage
• Total Diagnosed Prevalent Cases of HDV
• Gender-specific Diagnosed Prevalent Cases of HDV
• Age-specific Diagnosed Prevalent Cases of HDV
• Diagnosed Prevalent Cases of HDV by Impact on Liver
• Treated Cases of HDV
KOL-Views
We interview KOL’s and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM concerning the patient population of HDV?
• What are the key findings of the HDV epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients of HDV across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of HDV?

Reasons to buy
The HDV Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global HDV market
• Quantify patient populations in the global HDV market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the gender that presents the best opportunities for HDV therapeutics in each of the markets covered
• Understand the magnitude of the HDV population by its severity
• The HDV epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The HDV Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
• In the year 2017, the total diagnosed prevalent case of HDV was 204,976 cases in the 7MM, and the US, in 2017, accounted for 112,673 cases (the highest number), which will probably rise during the study period, i.e., 2017–2030.
• In the 7MM, the total gender-specific diagnosed prevalent cases of HDV were 129,470 for males and 75,506 for females in the year 2017.
• In the 7MM, the Age-specific Diagnosed Prevalent Cases of HDV were 6,165, 52,598, 48,340, 51,462, 36,942, and 9,468 cases for the age group less than 18 years, 18–34 years, 35–44 years, 45–54 years, 55–64 years, and ?65 years, in 2017.
• In 2017, there were nearly 61,493 decompensated liver cases, and 143,483 Compensated Liver cases in the 7MM, which will probably rise during the study period, i.e., 2017–2030.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Hepatitis C Virus (HCV) - Market Insights, Epidemiology, and Market Forecast - 2030

  • $ 6950
  • December 2020
  • 305 pages

‘Hepatitis C Virus (HCV) - Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the HCV, historical and forecasted epidemiology as well as the HCV ...

  • United States
  • Japan
  • Hepatitis
  • Hepatitis Treatment
  • Industry analysis
  • Use Of Prescription Drugs
  • Drug Approval

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on